CooperCompanies Q3 FY2026: revenue up 1.0%, GAAP EPS $2.24 on tax benefit
CooperCompanies grew revenue just 1.0% to $1.066 billion and its headline GAAP profit was inflated by a one-time $307.2 million U.K. tax benefit, while non-GAAP EPS rose 4.0% to $1.15. Guidance for the fourth quarter sits roughly flat versus this quarter and below the consensus next-quarter figure of $1.079 billion, so the read-through is steady cash generation, muted top-line momentum.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $2.24 versus $0.49 looks spectacular, but the company attributes it to a $307.2 million discrete tax benefit from completing a U.K. tax examination. The cleaner number is non-GAAP EPS of $1.15, up 4.0% from $1.10, with net income of $221.5 million on a non-GAAP basis against $432.8 million GAAP. Nine-month GAAP EPS is $2.49 and nine-month non-GAAP EPS is $3.46, which is the better base for judging the year.
Revenue of $1.066 billion rose 1.0% from $1.060 billion a year ago, with 1.0% organic growth and no currency help. CooperVision was flat at $717.0 million as reduced U.S. channel inventory offset growth elsewhere, while CooperSurgical grew 3.0% organically to $349.2 million. Gross margin improved to 66.8% from 65.3%, but the company says the prior-year gap was mostly old inventory write-offs, and non-GAAP gross margin actually fell 60 basis points.
The company guided fiscal fourth quarter revenue to $1.057–$1.080 billion, essentially flat versus this quarter's $1.066 billion, with CooperVision organic revenue of -2% to 0% and CooperSurgical of +4% to +6%. Full fiscal 2026 revenue guidance is $4.229–$4.252 billion and non-GAAP EPS guidance is $4.51–$4.55. Management flagged that the U.S. CooperVision inventory reduction will keep weighing on the fourth quarter.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.